Bruker Corporation (BRKR)

Bruker Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	340.1	488.3	645.5	1,068	681.8	678.3
Short-Term Investments	0	0	0	100	50	6.6
Cash & Cash Equivalents	340.1	488.3	645.5	1,168	731.8	684.9
Cash Growth	-43.12%	-24.35%	-44.74%	59.63%	6.85%	112.44%
Receivables	581	583.5	574.3	416.9	335.3	362.2
Inventory	1,061	968.3	800.1	710.1	692.3	577.2
Other Current Assets	158.8	124.1	93.3	176.6	165.6	172
Total Current Assets	2,140	2,164	2,113	2,472	1,925	1,796
Property, Plant & Equipment	691.2	691.4	538.2	466	462.9	371.7
Goodwill and Intangibles	1,201	913.1	728.5	551.3	549.5	526.2
Other Long-Term Assets	473.7	481.2	231.9	160.9	111.6	77.3
Total Long-Term Assets	2,366	2,086	1,499	1,178	1,124	975.2
Total Assets	4,506	4,250	3,612	3,650	3,049	2,772
Accounts Payable	199.1	202.7	178.4	147.4	134.6	118.4
Deferred Revenue	485.2	400	370.2	50.2	50.9	42.8
Current Debt	21.2	121.2	18.7	112.4	2.2	0.5
Other Current Liabilities	477	478.2	347	628.5	604.2	483.9
Total Current Liabilities	1,183	1,202	914.3	938.5	791.9	645.6
Long-Term Debt	1,443	1,235	1,235	1,264	889.3	859.8
Other Long-Term Liabilities	430.1	399.4	330.4	363.3	393.5	349
Total Long-Term Liabilities	1,873	1,635	1,566	1,627	1,283	1,209
Total Liabilities	3,056	2,837	2,480	2,565	2,075	1,854
Total Debt	1,464	1,356	1,254	1,376	891.5	860.3
Debt Growth	19.13%	8.16%	-8.87%	54.35%	3.63%	152.21%
Retained Earnings	2,367	2,324	1,926	1,660	1,407	1,275
Comprehensive Income	-7.7	6	14.8	-8.2	3.7	-25.5
Shareholders' Equity	1,415	1,377	1,114	1,071	961.2	906.8
Net Cash / Debt	-1,124.1	-868	-608.5	-207.8	-159.7	-175.4
Net Cash Per Share	-7.70	-5.90	-4.07	-1.36	-1.03	-1.12
Working Capital	957.9	962.1	1,199	1,533	1,133	1,151
Book Value Per Share	9.75	9.41	7.50	7.07	6.27	5.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).